Core Viewpoint - A class action lawsuit has been filed against Perpetua Resources Corp. on behalf of shareholders who purchased securities between April 17, 2024, and February 13, 2025, due to alleged misrepresentation of the costs associated with the Stibnite Gold Project [1][5]. Group 1: Lawsuit Details - The lawsuit claims that during the class period, Perpetua Resources Corp. provided misleading information regarding the true costs of the Stibnite Gold Project, particularly concerning inflation impacts and undisclosed decisions that led to a significant increase in projected initial capital expenses [5]. - Investors are encouraged to join the class action, which allows them to seek compensation without upfront costs through a contingency fee arrangement [2][3]. Group 2: Legal Representation - The Rosen Law Firm, known for its success in securities class actions, is representing the investors and emphasizes the importance of selecting qualified legal counsel with a proven track record [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been consistently ranked among the top firms in securities class action settlements [4]. Group 3: Next Steps for Investors - Interested investors can join the class action by visiting the provided link or contacting the firm directly for more information [3][6]. - It is noted that no class has been certified yet, and investors have the option to select their counsel or remain absent from the class [7].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Quantum Computing Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][3]. Group 1: Class Action Details - Investors who purchased Quantum Computing securities between March 30, 2020, and January 15, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 28, 2025 [3][5]. - The lawsuit alleges that Quantum Computing made false and misleading statements regarding its technologies, relationships with NASA, and business dealings, which led to investor damages when the truth was revealed [5]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in securities class action settlements [4].

NEW YORK, March 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds of purchasers of securities of Maravai Lifesciences Holdings, Inc. (NASDAQ: MRVI) between August 7, 2024 and February 24, 2025, both dates inclusive (the “Class Period”), of the important May 5, 2025 lead plaintiff deadline. SO WHAT: If you purchased Maravai securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

INDIANA, Pa., March 20, 2025 /PRNewswire/ -- S&T Bank, the wholly owned subsidiary of S&T Bancorp Inc. (NASDAQ, STBA), has announced its naming as a 2025 USA Today Top Workplace. This recognition is based on anonymous employee feedback from a research-based survey issued by Energage. Top Workplaces recognizes organizations that have created outstanding workplace cultures, and this marks the second time the Bank has won this award, first being named to the prestigious list in 2023."Being again listed as a To ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Novo Nordisk securities between November 2, 2022, and December 19, 2024, about the upcoming lead plaintiff deadline of March 25, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Novo Nordisk securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by March 25, 2025 [2]. - The lawsuit claims that during the class period, defendants made misleading statements regarding the phase 3 CagriSema study on obesity, particularly about the expected outcomes and the trial protocol [4]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. - Investors have the option to select their counsel or remain absent from the class without affecting their ability to share in any potential recovery [6].

Group 1 - The Rosen Law Firm is reminding purchasers of FMC Corporation securities from November 16, 2023, to February 4, 2025, about the April 14, 2025, lead plaintiff deadline for a class action lawsuit [1] - Investors who purchased FMC securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1][2] - The lawsuit alleges that FMC made false and misleading statements regarding its channel management initiatives and pricing strategies, leading to inflated inventory levels in various regions [4] Group 2 - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone, and has been recognized for its performance in securities class action settlements [3] - The lawsuit claims that when the true details about FMC's business practices were revealed, investors suffered damages due to the misleading statements made by the defendants [4]

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of Ready Capital Corporation (NYSE: RC) between November 7, 2024 and March 2, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 5, 2025. SO WHAT: If you purchased Ready Capital securities during ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Edison International securities between February 25, 2021, and February 6, 2025, about the upcoming lead plaintiff deadline for a securities class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Edison securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 21, 2025 [3] - The lawsuit alleges that Edison made materially false and misleading statements regarding its Public Safety Power Shutoffs program, which purportedly increased fire risk and legal exposure [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased TELUS International securities between February 16, 2023, and August 1, 2024, of the March 31, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased TELUS International securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is March 31, 2025, with the lead plaintiff acting on behalf of other class members [3]. Group 2: Case Allegations - The lawsuit alleges that TELUS International failed to disclose that its AI Data Solutions offerings cannibalized higher-margin products, leading to declining profitability [5]. - It is claimed that the shift towards AI increased pressure on the company's margins more than previously disclosed, resulting in misleading positive statements about the company's business and prospects [5].

Core Insights - Amgen and Kyowa Kirin announced positive results from the ROCKET Phase 3 clinical trial program for rocatinlimab, a T-cell rebalancing therapy for moderate to severe atopic dermatitis [1][2] Study Results - The IGNITE study demonstrated that both dose strengths of rocatinlimab met co-primary and key secondary endpoints, showing statistical significance against placebo [2] - At week 24, 42.3% of patients in the higher dose group achieved ≥75% reduction in Eczema Area and Severity Index (EASI-75), a 29.5% improvement over placebo (p < 0.001) [3] - In the lower dose group, 36.3% achieved EASI-75, a 23.4% improvement over placebo (p < 0.001) [3] - For the validated Investigator's Global Assessment for Atopic Dermatitis (vIGA-AD™), 23.6% of the higher dose group achieved a score of 0 or 1, a 14.9% difference from placebo (p < 0.001) [4] - The lower dose group had 19.1% achieving this endpoint, a 10.3% difference from placebo (p = 0.002) [4] - The revised Investigator's Global Assessment (rIGA™) score of 0/1 was achieved by 22.7% of the higher dose group, a 14.4% difference from placebo (p < 0.001) [5] - In the lower dose group, 16.3% achieved this endpoint, an 8.0% difference from placebo (p = 0.01) [5] Safety Profile - Safety findings were consistent with previous observations, with common treatment-emergent adverse events including pyrexia, chills, and headache [6] - Gastrointestinal ulceration events were reported in a higher number of patients receiving rocatinlimab compared to placebo, with an overall incidence of less than 1% [6] Future Trials - The ASCEND trial will investigate the long-term effects of rocatinlimab beyond 24 weeks, including maintenance of clinical response [6] - The ASTRO and ORBIT trials will evaluate rocatinlimab in adolescent patients [6] Additional Studies - The SHUTTLE study also met its co-primary endpoints, showing significant efficacy for rocatinlimab in combination with topical corticosteroids [7] - In SHUTTLE, 52.3% of patients in the higher dose group achieved EASI-75, a 28.7% difference from placebo (p < 0.001) [7] - The VOYAGER study confirmed that rocatinlimab does not interfere with responses to certain vaccinations [9] About Rocatinlimab - Rocatinlimab is an anti-OX40 human monoclonal antibody targeting T-cell imbalance in atopic dermatitis and other conditions [13] - It is being studied for multiple indications, including moderate to severe uncontrolled asthma and prurigo nodularis [13]